Clinical

The hesitation to prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to patients with hemophilia is not supported by current research, based on a recently published review, but the available studies had significant limitations.

The increasing rate of melanoma diagnosis may not be due to actual disease, the authors of a new study posit; instead, it may be due to overdiagnosis of patients with an actual very low risk of death.

This new report also shows the value of national databases tracking the use of ventilation support.

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitor use in people with type 1 diabetes.

Although the understanding of chronic graft-versus-host disease (GVHD) has improved in recent years, more work is needed to facilitate personalized treatments for patients after hematopoietic stem cell transplantation (HSCT).

A new report has found continuous glucose monitoring (CGM) may help reduce staff burden in the intensive care unit (ICU) by reducing the need for blood gas monitoring.

The investigators of a new study evaluated if nasal cytology was a reliable method to identify type 2 inflammation in patients who have chronic rhinosinusitis with nasal polyps (CRSwNP), which could then facilitate patient selection for biological drug utilization via endotypization.

The new data suggest risdiplam can be a viable option for people with spinal muscular atrophy who cannot take or tolerate the 2 other approved disease-modifying therapies.

The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.

Zanubrutinib is the latest of 3 Bruton tyrosine kinase (BTK) inhibitors approved for rare B-cell malignancies, such as Waldenström macroglobulinemia, a non-Hodgkin B-cell lymphoma (NHBCL); as a next-generation BTK inhibitor, zanubrutinib is designed to have less off-target effects.

While chimeric antigen receptor (CAR) T-cell therapy has offered a new option and improved outcomes for patients with advanced hematologic malignancies, the treatment approach has been associated with toxicities such as cytokine release syndrome (CRS), neurotoxicity, and hematotoxicity.

A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.

Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.

Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, professor of medicine and the Gerald S. Berenson Endowed Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the results of the recently halted FRESH trial, why there is such a great need for new antihypertensive agents, and possible contributory factors to outcome disparities between Black and White patients.

Major depressive disorder treatment failure can lead to subsequent costs and poor outcomes, affecting payer considerations in the treatment landscape.

A panel at the annual American Heart Association conference held in Chicago, Illinois, discussed ways in which cardiovascular disease (CVD) care was affected by equity issues between White and Black patients.

Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Posters presented at the American Heart Association conference in Chicago, Illinois, evaluated the insights from the VICTORIA trial and their generalizability to patients hospitalized with heart failure with reduced ejection fraction (HFrEF).

Recent research suggested the idea of combining chimeric antigen receptor (CAR) T-cell therapy and Bruton’s tyrosine kinase (BTK) inhibitors for certain patients with advanced mantle cell lymphoma (MCL).

Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression of CKD.

Colombia and Brazil had the highest prevalence and incidence of systemic lupus erythematosus (SLE), a new investigation found.

Children and families living in low-income neighborhoods have the highest rate of respiratory syncytial virus (RSV) hospitalizations, according to researchers.

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of death or worsening progression of chronic kidney disease (CKD) by 28%, according to results published Friday at Kidney Week 2022.

The SOGUG-AUREA study explored overall survival of atezolizumab plus split-dose cisplatin-gemcitabine in patients with locally advanced and metastatic urothelial cancer.

Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer.

The probability of drug interactions increases when genetic polymorphisms are considered, indicating that pharmacogenetic assessment may be useful in predicting the presence and severity of interactions.

A new report found interesting links between genetic factors associated with COVID-19 severity and autoimmune disease among persons who have systemic lupus erythematosus (SLE).

The American Heart Association (AHA) will hold its annual conference in person in Chicago and online from November 5-7, with sessions on health equity and gene editing receiving particular focus.

Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.